Reports FY22 revenue $5.091M, consensus $4.67M. "We are thrilled to partner with GSK, a leading global organization in the fight against infectious diseases, an area of increasing public health urgency," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "For SCYNEXIS and our shareholders, this deal is transformational and creates significant value, both strengthening our balance sheet and enhancing the opportunity to deliver additional innovative therapies to patients with unmet needs. We will continue advancing ibrexafungerp clinical programs and are in a strong financial position to execute our strategic priorities this year and beyond. With our good track record of efficiently bringing to market first-in-class compounds and the additional resources on hand, our organization is well positioned to continue developing groundbreaking therapies, including our next generation fungerp SCY-247."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCYX:
- SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Scynexis price target raised to $10 from $7 at Maxim
- SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment
- Scynexis, GSK announce exclusive agreement to commercialize, develop Brexafemme
- GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection